ライフサイエンスコーパス: curative therapy

1 ents remains poor with short survival and no curative therapy.

2 ancer is notorious for recurrence even after curative therapy.

3 ion people worldwide, HIV-1 infection has no curative therapy.

4 ctory prostate cancer, for which there is no curative therapy.

5 , and currently remains the only potentially curative therapy.

6 gressive primary brain tumor with no current curative therapy.

7 only those men with significant cancers for curative therapy.

8 atedly interpreted as providing evidence for curative therapy.

9 lar pancreatic cancer, which lacks effective curative therapy.

10 ith stem cell transplantation being the only curative therapy.

11 ith stem cell transplantation being the only curative therapy.

12 plantation is currently the only potentially curative therapy.

13 in the abdomen, a characteristic that limits curative therapy.

14 h may lead to novel strategies for improving curative therapy.

15 tectomy have redefined the goal of TARE as a curative therapy.

16 liver failure, and there remains no reliable curative therapy.

17 ge in the complex process leading up to this curative therapy.

18 portant to identify more people eligible for curative therapy.

19 haustion is largely irreversible, even after curative therapy.

20 major cause of disability worldwide with no curative therapy.

21 st as memory in both compartments long after curative therapy.

22 n of marginalized communities and expediting curative therapy.

23 ients are otherwise eligible for potentially curative therapy.

24 and to adapt therapy, notably indication of curative therapy.

25 nstrates the potential of targeted JAKi as a curative therapy.

26 tion of MDS HSCs is an important part of any curative therapy.

27 cell transplantation might be a potentially curative therapy.

28 the epileptogenic focus represents the only curative therapy.

29 thritis is a common, complex disease with no curative therapy.

30 isease with high public health burden and no curative therapy.

31 an 85% of adults worldwide with no permanent curative therapy.

32 istant urothelial carcinoma has no uniformly curative therapy.

33 epresents a significant clinical obstacle to curative therapy.

34 Bone marrow transplantation is the only curative therapy.

35 applies to patients with MT-GCT treated with curative therapy.

36 nfected cells that persist after potentially curative therapy.

37 e showing significant promise as potentially curative therapy.

38 r really have an opportunity for a potential curative therapy.

39 e and palliative care, and limited access to curative therapies.

40 th bladder cancer do not receive potentially curative therapies.

41 in the absence of effective preventative or curative therapies.

42 of retinal degeneration that currently lack curative therapies.

43 cer (NSCLC) being considered for potentially curative therapies.

44 ellular carcinoma (HCC) patients who receive curative therapies.

45 o address the unmet need for preventative or curative therapies.

46 ading to limited availability of options for curative therapies.

47 results in increased probability to undergo curative therapies.

48 tion of this cell population is required for curative therapies.

49 and cancer worldwide for which there are no curative therapies.

50 causal mechanisms is critical to developing curative therapies.

51 ligible or unresponsive to current intensive curative therapies.

52 and fit AML patients eligible for intensive curative therapies.

53 ioration of respiratory functions that lacks curative therapies.

54 of progression, and potential preventive or curative therapies.

55 voir for infectious virus and an obstacle to curative therapies.

56 taking decisions on efficient preventive and curative therapies.

57 tion of this cell population is required for curative therapies.

58 of virus cell entry and open new avenues for curative therapies.

59 /E7 vaccines already in clinical trials into curative therapies.

60 has produced limited clinical benefit and no curative therapies.

61 problem in the United States; yet, the only curative therapy, a bone marrow transplant (BMT), is sel

62 ng ovarian cancer represent complications of curative therapies and/or underlying susceptibility stat

63 recurrent cervical carcinoma not amenable to curative therapy and at least one prior regimen in the m

64 Treatment measures such as curative therapy and case isolation exert selective pres

65 as not required for immunologically specific curative therapy and induction of memory provided that a

66 fferences impact eligibility for potentially-curative therapy and prognosis.

67 Hepatitis flares may occur during curative therapy and should be promptly investigated and

68 ges, and is associated with lower receipt of curative therapy and with poorer survival, current socie

69 iagnosis and linkage to care, development of curative therapies, and removal of stigma are important

70 ederal regulations require patients to forgo curative therapies, and they interpret phase I agents as

71 e on early stage tumor detection, receipt of curative therapy, and overall survival in patients with

72 vements in early tumor detection, receipt of curative therapy, and overall survival in patients with

73 JMML remains a disease for which few curative therapies are available other than myeloablativ

74 ts in significant neurological deficits, and curative therapies are lacking.

75 radiologists to detect smaller tumors, when curative therapies are most effective.

76 Curative therapies are most successful when cancer is di

77 Curative therapies are needed and ideally should induce

78 ncreatic cancer is often detected late, when curative therapies are no longer possible.

79 is is important because effective, and often curative, therapies are available for many subtypes.

80 For both forms of XLP, the only curative therapy at present is allogeneic hematopoietic

81 There are no curative therapies available to resolve chronic HBV infe

82 nding of the tauopathies, there are still no curative therapies available.

83 osis would prompt a shift from palliative to curative therapies based around surgery and radiotherapy

84 Two potentially curative therapies based on gene therapy and gene editin

85 ers are not yet treatable and/or are without curative therapies because of our limited understanding

86 atients for appropriate disease-modifying or curative therapies before they have irreversible neurolo

87 matopoietic stem cell transplant is the only curative therapy, but it is limited by donor availabilit

88 Liver transplantation (LT) is the only curative therapy, but outcomes are compromised by recurr

89 transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complic

90 y predisposition in SCD and help ensure that curative therapies can be more safely applied.FUNDINGNew

91 riven proliferation of T-effector cells, but curative therapy can be achieved in nonconditioned hosts

92 Because a curative therapy can be offered to these patients (ie, b

93 The current absence of curative therapies capable of resolving chronic hepatis

94 Tumor recurrence following potentially curative therapy constitutes a major obstacle to achievi

95 ntify and treat more eligible candidates for curative therapy could be beneficial.

96 egenerative disorders for which no effective curative therapy currently exists.

97 Curative therapy depends on control of the primary tumou

98 f 11 patients (28%) who received potentially curative therapy died, compared with 62 of 71 patients (

99 stance within persisting tumor cells renders curative therapies elusive for the majority of women wit

100 myeloma is a B-cell malignancy for which no curative therapies exist to date, despite enormous resea

101 lindness and visual impairment worldwide, no curative therapies exist.

102 Curative therapy exists even in patients with resistant

103 mains a challenge to clinical medicine, with curative therapy experienced by a minority of patients.

104 ugh international clinical trials, effective curative therapies for about half of patients with sever

105 ecreased mortality, there remains a need for curative therapies for active infections.

106 The lack of curative therapies for acute myeloid leukaemia (AML) rem

107 urpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in

108 One key barrier to curative therapies for HIV is the limited understanding

109 ht enable the development of next-generation curative therapies for individuals with cancer.

110 on and disabling disorder of the CNS with no curative therapies for its progressive form.

111 gets for the development of preventative and curative therapies for Lyme disease.

112 Current models predict that curative therapies for many cancers will require the eli

113 ctious diseases has the potential to lead to curative therapies for many previously untreatable disea

114 There are no curative therapies for TBD patients.

115 resent a path forward for the development of curative therapies for the majority of cancer patients.

116 en-specific regulatory T cells could provide curative therapies for these problems.

117 Currently, there are no preventive or curative therapies for this dominantly inherited disease

118 Currently, there are no curative therapies for this fatal disease.

119 How dangerous does a potentially curative therapy for a fatal illness need to be before w

120 ic BM transplantation, and thereby provide a curative therapy for a wide spectrum of human diseases.

121 Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL).

122 ensive research, but so far no preventive or curative therapy for AD is available, and clinical trial

123 mpared in patients who underwent potentially curative therapy for adenocarcinoma of the pancreatic he

124 Currently, there is no accepted curative therapy for ATL.

125 There is no accepted curative therapy for ATL.

126 Presently, there is no accepted curative therapy for ATL.

127 Presently, there is not an accepted curative therapy for ATL.

128 oietic stem cell transplantation (HSCT) is a curative therapy for blood and immune diseases with pote

129 Curative therapy for cancer patients with advanced-stage

130 ell transplantation (HCT) may offer the only curative therapy for certain life-threatening immune def

131 liver transplantation is currently the only curative therapy for chronic end-stage liver disease and

132 one marrow transplantation (BMT) is the only curative therapy for chronic myelogenous leukemia (CML),

133 marrow transplantation (BMT) offers the only curative therapy for chronic myelogenous leukemia.

134 c blood or marrow transplantation (BMT) is a curative therapy for chronic myeloid leukemia (CML).

135 geneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia.

136 Despite intensive efforts in recent years, a curative therapy for cutaneous T-cell lymphoma (CTCL) ha

137 Curative therapy for diabetes mellitus mainly implies re

138 urvival outcomes between patients undergoing curative therapy for HCC in the background of NASH compa

139 cal science which allowed the development of curative therapy for HCV, that will save countless lives

140 y has become an integral part of potentially curative therapy for head and neck cancer and has been i

141 opoietic cell transplantation, a potentially curative therapy for hematologic diseases.

142 Reduced intensity has allowed a potentially curative therapy for hematologic malignancies to be offe

143 c stem cell (HSC) transplantation is used as curative therapy for hematologic malignancies.

144 blood and marrow transplantation (BMT) as a curative therapy for hematological malignancies lies in

145 bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancies, but is

146 transplantation (allo-HSCT) is a potentially curative therapy for hematological malignancies.

147 rgical excision remains the only potentially curative therapy for hepatic malignancies.

148 diofrequency ablation (RFA) is a potentially curative therapy for hepatocellular carcinoma (HCC).

149 atectomy is safe, effective, and potentially curative therapy for hepatocellular carcinoma.

150 tem cell transplantation is a cornerstone of curative therapy for high-risk and/or advanced hematolog

151 ll transplantation (alloSCT) is an important curative therapy for high-risk hematological malignancie

152 ains the most effective and only potentially curative therapy for hilar cholangiocarcinoma.

153 Solid organ transplantation is a curative therapy for hundreds of thousands of patients w

154 transplantation (HSCT) is the gold standard curative therapy for infants and children with many inbo

155 iate]), who received no previous potentially curative therapy for leukaemia.

156 es to evolve as an effective and potentially curative therapy for limited numbers of patients with re

157 tic stem cell transplantation is a potential curative therapy for malignant and nonmalignant diseases

158 itor cell (HSPC) transplantation serves as a curative therapy for many benign and malignant hematopoi

159 ll transplantation (HSCT) holds promise as a curative therapy for many JAK-STAT pathway disorders, bu

160 c stem cell transplantation is a potentially curative therapy for many malignant and non-malignant he

161 ntation of cord blood provides a potentially curative therapy for many patients without a suitably hu

162 Curative therapy for metastatic cancers is equivalent to

163 nd currently represents the only potentially curative therapy for metastatic colorectal cancer.

164 Currently, no curative therapy for metastatic prostate cancer exists.

165 ietic cell transplantation (HCT) is the only curative therapy for MF.

166 ith thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ

167 Traditionally, curative therapy for most renal cancers involved open ra

168 oietic stem cell transplantation is the only curative therapy for myelodysplasia (MDS).

169 stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS).

170 ransplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), al

171 ansplantation (HSCT) is the only potentially curative therapy for myelofibrosis.

172 system after transplantation(1), which is a curative therapy for numerous diseases including immunod

173 ellular immunotherapy (ACT) is a potentially curative therapy for patients with advanced cancer.

174 etic stem cell transplantation (HSCT) offers curative therapy for patients with hemoglobinopathies, c

175 ron-sparing surgery (NSS) provides effective curative therapy for patients with localized renal cell

176 etic cell transplantation offers potentially curative therapy for patients with myelodysplastic syndr

177 HSCT represents a curative therapy for patients with MYSM1 deficiency.

178 lthough surgery remains the only potentially curative therapy for patients with primary GEP-NETs, oth

179 PURPOSE Surgery is curative therapy for pediatric low-grade gliomas (LGGs)

180 cell transplantation (HCT) is a potentially curative therapy for peripheral T-cell lymphoma; however

181 neic bone marrow transplantation is the only curative therapy for PNH.

182 opoietic stem cell transplantation, the only curative therapy for SCD and Thal, is limited by the abs

183 c cell transplantation is, to date, the only curative therapy for SCD, but its application is limited

184 ransplantation (alloHCT) represents the only curative therapy for several hematologic malignancies, a

185 cell transplantation (HSCT) is a potentially curative therapy for several malignant and non-malignant

186 Additionally, HSCT has been a curative therapy for several nonmalignant hematologic di

187 e cyclophosphamide (Cy) has been promoted as curative therapy for severe aplastic anemia (SAA).

188 ate human epidermis after transplantation, a curative therapy for severe burns and, recently, disease

189 The only curative therapy for sickle cell disease (SCD) is alloge

190 one marrow transplantation (BMT) is the only curative therapy for sickle cell disease (SCD).

191 nib and, to date, there remains no effective curative therapy for systemic mastocytosis associated wi

192 ic cell transplantation provides potentially curative therapy for t-MDS, but additional improvements

193 se (NCDB), we examined patients who received curative therapy for the following sites: oral tongue, o

194 marrow transplantation is currently the only curative therapy for the hematopoietic complications of

195 murafenib response with the ultimate goal of curative therapy for the subset of melanoma patients wit

196 he potential of evoking memory response as a curative therapy for the treatment of CRC liver metastas

197 arrow transplantation remains the only known curative therapy for these patients and the use of reduc

198 in Yoshihara et al., holds the promise of a curative therapy for this disease.

199 e therapy does appear feasible and may offer curative therapy for those with refractory and relapsed

200 cess of islet transplantation as a potential curative therapy for type 1 diabetes.

201 ment by islet transplantation is a potential curative therapy for type 1 diabetes.

202 ficant potential for INE963 (1) to provide a curative therapy for uncomplicated malaria with short do

203 onfined to regional lymph nodes, there is no curative therapy for widely metastatic disease.

204 Nevertheless, curative therapy has remained elusive for important path

205 ded to the general population, and intensive curative therapies have become the standard.

206 anemia has been known for 7 decades, yet no curative therapies have been available other than alloge

207 of neuromuscular diseases are well known, no curative therapies have been developed to date.

208 transplantation (BMT) is currently the only curative therapy; however, toxic myeloablative precondit

209 strong similarity to the empirically-derived curative therapy in childhood acute lymphocytic leukemia

210 ntial to vastly increase the availability of curative therapy in CLL while retaining a low treatment-

211 atients with R/R iNHL and its potential as a curative therapy in FL.

212 model will serve to accelerate emerging HBV curative therapies into the clinic.

213 reatment paradigms, and deintensification of curative therapy is a current research focus for these p

214 Curative therapy is achievable in 90% of affected childr

215 The only curative therapy is allogeneic transplantation.

216 No curative therapy is available for malignant gliomas.

217 No curative therapy is currently available for AGU.

218 onal myeloid-disabling disorder for which no curative therapy is currently available.

219 When potentially curative therapy is no longer an option, the patient, fa

220 Athough curative therapy is now available for hepatitis C virus

221 rlier diagnosis, which may allow potentially curative therapy, is necessary.

222 ize, such that surgery, the only potentially curative therapy, is not possible.

223 neic hematopoietic cell transplantation is a curative therapy limited by graft-versus-host disease (G

224 n early stage are candidates for potentially curative therapies (local ablation, resection, or transp

225 tients, but the efficacy of this potentially curative therapy may be limited by poor persistence of T

226 ifferences in recurrence-free survival after curative therapy (median, 60 versus 56 months; P = 0.303

227 With hepatitis C (HCV) curative therapy, more potential donors may now be suita

228 Patients who underwent curative therapy (mostly allogeneic hematopoietic stem c

229 showed that 20.1% of patients without prior curative therapy (n = 1163) developed at least 1 manifes

230 abling that patients drop out of potentially curative therapy, negatively impacting cancer prognosis.

231 This represents a possibly curative therapy of an autoimmune disease via selective

232 r stem cells is believed to be essential for curative therapy of cancers, but supporting evidence is

233 tegies besides Bcr-Abl kinase inhibition for curative therapy of CML.

234 alkylating agents have a central role in the curative therapy of many human tumors; yet, resistance t

235 c stem cell transplantation remains the only curative therapy of MF, but due to its associated morbid

236 ses, stem cell pathways must be targeted for curative therapy of Ph(+) leukemia.

237 and suggest that development of a long-term curative therapy of prostate cancer may be possible by k

238 the clinical course, and offer prospects for curative therapy of sickle cell disease.

239 life-threatening pathogen that still lacks a curative therapy or vaccine.

240 ital anemias for which there is presently no curative therapy other than allogeneic hematopoietic ste

241 To obtain curative therapy, other effective agents, based on HL bi

242 62 of 71 patients (87%) who did not receive curative therapy (P = .0001).

243 ificant differences in treatment allocation (curative therapy, palliative therapy, and best supportiv

244 patients with stage IV lung cancer, into the curative therapy paradigm has lagged owing to inefficien

245 in order to design safer and more effective curative therapy, particularly for children with SCID di

246 pump, whereas in tumors relapsing after non-curative therapy, poor drug sensitivity is most commonly

247 No curative therapy presently exists.

248 Further, as potentially curative therapies require RBC transfusions to lower the

249 e (41.2% vs. 30.9%), or received potentially curative therapy (resection, transplantation), compared

250 The absence of curative therapy results in lifelong carriage marked by

251 ults with severe SCD, reasonable alternative curative therapy should be considered for children and a

252 g access to diagnostic testing and to timely curative therapies such as surgical mitral valve repair

253 ge disease and currently receive potentially curative therapies, such as resection, liver transplanta

254 nosed at early stage and receive potentially curative therapies, such as surgical resection and liver

255 Many patients are not eligible for curative therapies, such as surgical resection of the tu

256 nificantly higher before the commencement of curative therapy than after therapy.

257 Curative therapy, thanks to insights into the molecular

258 vior, treatment coverage, and the effects of curative therapies that also block Plasmodium parasite t

259 kle cell disease (SCD) do not have access to curative therapies, the availability of drug therapies t

260 mmatory response that largely decreases with curative therapy, though some analytes persisted above t

261 eted AVID platform may enable development of curative therapies through in vivo gene correction in hu

262 ions with potential to reduce anti-Wolbachia curative therapy times to between one and two weeks.

263 This underscores the need to develop curative therapies to improve quality of life and longev

264 Among possible curative therapies, traditional antiretroviral therapy,

265 Despite widespread availability of curative therapy, tuberculosis (TB) treatment outcomes r

266 verage should be prioritized to increase HCV curative therapy uptake for persons with HIV.

267 Novel curative therapies using genetic transfer of normal glob

268 an duration of persistence in the absence of curative therapy was 143 days (range, 21-228).

269 Curative therapy was achieved with doses of 101M that di

270 mediate or high grade, for which no standard curative therapy was available, an Eastern Cooperative O

271 osis and offering these patients potentially curative therapy wherever appropriate is of utmost impor

272 Patients with PC not amenable to curative therapy who had received no prior therapy for m

273 The safety of any new curative therapies will be paramount given the excellent

274 Curative therapy with allogeneic haematopoietic stem cel

275 ts with HCC who are eligible for potentially curative therapy with liver resection or ablation should

276 splantation (alloHSCT) is the only available curative therapy, with benefits derived from the antigen

277 e given the opportunity to have a definitive curative therapy within validated criteria.

278 er years, suggesting that a prerequisite for curative therapies would be to overcome not only tumor h